---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-081976"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2022-12-22T23:59:59+00:00"
generated_at: "2026-06-21T00:00:54.361265+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NeuroOne reports fiscal Q4 2022 net loss of $1.4M; collaboration revenue jumps to $1.94M

## Summary
- Product revenue $69K in Q4 vs $48K prior year; full year $171K vs $178K.
- Collaboration revenue $1.94M in Q4 from Zimmer Development Agreement, up from $5K.
- Net loss $1.4M in Q4 vs $2.6M prior year; full year net loss $10.0M vs $9.9M.
- Cash and short-term investments $11.1M at Sept. 30, 2022, up from $6.9M; no debt outstanding.
- Operating expenses $3.3M in Q4 vs $2.6M; R&D $1.4M, SG&A $1.9M.

## SEC filing metadata
- accession: 0001213900-22-081976
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2022-12-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390022081976/0001213900-22-081976-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390022081976/ea170126-8k_neuroone.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-081976
- JSON: https://secwatch.observer/filing/0001213900-22-081976.json
- Plain text: https://secwatch.observer/filing/0001213900-22-081976.txt

## Key facts
- Earnings Releases
  NEUROONE MEDICAL TECHNOLOGIES Corp reported fiscal year ended September 30, 2022 results: net income $10.0 million.
  - Period: fiscal year ended September 30, 2022
  - Net income: $10.0 million
  - Result: reported results
  source text: Net loss was $10.0 million for the full year fiscal 2022, compared to a net loss of $9.9 million in fiscal 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1500198/000121390022081976/0001213900-22-081976-index.htm
- Earnings Releases
  NEUROONE MEDICAL TECHNOLOGIES Corp reported fiscal fourth quarter ended September 30, 2022 results: net income $1.4 million.
  - Period: fiscal fourth quarter ended September 30, 2022
  - Net income: $1.4 million
  - Result: reported results
  source text: Net loss was $1.4 million for the fourth quarter of fiscal 2022, compared to a net loss of $2.6 million in the prior year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1500198/000121390022081976/0001213900-22-081976-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.